HERZLIYA, ISRAEL AND CALGARY, ALBERTA, Oct. 11, 2024 /CNW/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”) is a member of the pharmaceutical industry. and the biotech industry announce promising results from multi-year compassionate therapy of repeated injections of liposomal CBD (LPT-CBD) to reduce pain in dogs with naturally occurring osteoarthritis I'm happy to be able to do this. This treatment consistently demonstrated pain relief and improved mobility, and as expected, the effects lasted for several weeks after each injection. These results further demonstrate that LPT-CBD can be a viable treatment option to manage chronic pain and improve quality of life in animals.
LPT-CBD is a monthly injection treatment that may achieve superior bioavailability by avoiding first-pass liver metabolism.
In two ongoing cases, dogs suffering from osteoarthritis treated with LPT-CBD after failing to respond to nonsteroidal anti-inflammatory drugs (NSAIDs) and oral CBD experienced significant pain relief, It showed a significant improvement in mobility, a clearly noticeable and positive increase in exercise capacity. There is. Both dogs continued LPT-CBD treatment for 2 and 2.5 years, respectively, after their owners reported a significant improvement in their quality of life after receiving the treatment in addition to conventional treatment. Previous pilot studies by Innocan have shown similar promising results.
Professor Chezy Barenholz, CSO of Innocan Pharma, commented: “We are excited by these findings, which highlight the long-lasting effects of repeated administration of LPT-CBD in the treatment of chronic pain.” “These results support the potential of LPT-CBD as a monthly treatment for chronic pain conditions, resulting in sustained relief. We are positioning it as a breakthrough solution for managing chronic pain.”
Dr. Eyal Caro, Innocan's Director of Research and Development, said, “This compassionate therapy has demonstrated significant efficacy in companion dogs, and the FDA Center for Veterinary Medicine's approval of LPT-CBD in the treatment of chronic pain in dogs. “This strengthens our commitment to advance CVM approvals.” ”
About Innocan Pharma:
Innocan is an innovator in the pharmaceutical and wellness space. In the pharmaceutical field, Innocan has developed a CBD-loaded liposomal drug delivery platform that precisely dose, sustained and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a broad portfolio of high-performance self-care and beauty products to promote healthier lifestyles. Under this segment, Innocan has established a joint venture (BI Sky Global Ltd) focused on advanced and targeted online sales.
For more information, please visit www.innocanpharma.com.
contact address:
For Innocan Pharma Corporation:
Iris Vinkovic, CEO
+1 5162104025
+972-54-3012842
+442037699377
(email protected)
Neither the Canadian Securities Exchange nor its regulatory services provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Caution regarding forward-looking information
Certain information contained in this news release, including without limitation the human testing plans for the Company's LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By their nature, forward-looking information involves a number of risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release reflects certain assumptions made by Innocan, including expectations and assumptions regarding the expected benefits of the product, the satisfaction of regulatory requirements in various jurisdictions, and the satisfactory completion of production and sales arrangements. based on key expectations and assumptions.
Forward-looking information is subject to various risks and uncertainties that could cause actual results or experience to differ materially from the anticipated results or expectations expressed in this news release. Principal risks and uncertainties include, but are not limited to: Governmental and Regulatory Requirements and Actions by Governmental Authorities. Relationships with suppliers, manufacturers, customers, business partners and competitors may be disrupted. There are also risks inherent to the nature of product distribution, such as import and export issues and the inability to obtain (or timely obtain) necessary regulatory or other approvals. Our anticipated schedule for market entry is subject to change for a variety of reasons, including the inability to secure necessary regulatory requirements and the need for additional time to enter into and/or satisfy manufacturing and distribution arrangements. . For the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks affecting Innocan is contained in Innocan's public reports and filings, which are available from Innocan's profile at www.sedarplus.ca.
Readers are cautioned not to place undue reliance on forward-looking information, as actual results may differ materially from such forward-looking information. Innocan does not undertake to update, amend or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law.
Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
SOURCE Innocan Pharma Corporation
